ABC, ATP-binding cassette; ABCG2, ATP-binding cassette sub-family G member 2; BCRP, Breast cancer resistance protein; P-gp, P-glycoprotein; Pp-18, purpurin-18; MRP1, Multidrug resistance protein 1; MPPa, pyropheophorbide a methyl ester; Estradiol, 17-β-estradiol; FTC, fumitremorgin C; ATPase, Adenosine triphosphatase.
Introduction
ABCG2 (also known as breast cancer resistance protein; BCRP) is an ATP-binding cassette (ABC) transporter localized to the plasma membrane that actively pumps a wide variety of molecules out of cells. ABCG2 was first identified in multidrug-resistant cancer cell lines (Polgar et al., 2008) , but it also plays a protective role at the maternal-fetal, blood-testis and blood-brain barriers by preventing the entry of small molecules (Kannan et al., 2009; Robey et al., 2009) . It facilitates absorption in the liver and limits absorption from the small intestine, and it is expressed in the mammary glands where it is responsible for active secretion of substrates into milk (Jonker et al., 2005) . ABCG2 function is responsible for the 'side-population' phenomenon observed in flow cytometry due to Hoechst 33342 efflux by hematopoietic cells with stem-cell-like characteristics (Natarajan et al., 2012) . When Abcg2 is absent in transgenic mice, the primary phenotype is photosensitivity, with phototoxic lesions due to the accumulation of endogenous porphyrin metabolites that would otherwise be excreted (Jonker et al., 2002) , and it was recently shown that Abcg2 mediates the transport of sulfate conjugates of phytoestrogens (Van de Wetering and Sapthu, 2012) . Polymorphic forms of ABCG2 are associated with gout because of decreased excretion of uric acid in the proximal tubule of the kidney (Woodward et al., 2009) . It was recently recognized that healthy individuals of the Jr(a)-blood type carry two null alleles of ABCG2 despite the important physiologic role understood for ABCG2 (Saison et al., 2012; Zelinski et al., 2012) . The functional consequences of ABCG2 loss are still unknown, but are not associated with obvious disease. In light of the roles of ABCG2 in drug resistance and normal physiology, further research on models aimed at understanding ABCG2 function is warranted.
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Cell lines expressing human ABCG2 are commonly used to study its function as an efflux pump or to screen for novel inhibitors (Deeken et al., 2009) . Fluorescent substrates have proven to be useful tools for measuring transporter function, and in vitro studies using these substrates are sometimes reported alongside pharmacokinetic assessments in Abcg2 knockout mice to study ABCG2 function in vivo (Kannan et al., 2010; Hall and Pike, 2011; Mairinger et al., 2011) . Abcg2-deficient mice have also been instrumental in elucidating the normal physiologic roles of ABCG2, such as its role in preventing oral drug absorption or brain penetration of substrates (Vlaming et al., 2009 ). The mouse ortholog of ABCG2 has 81% protein sequence homology with human ABCG2 (Allen et al., 1999 ) and a single amino acid mutation can alter the substrate and antagonist specificity in both species (Robey et al., 2003) , leading to the assumption that substrate and inhibitor profiles of human and murine ABCG2 are directly comparable. However, in the case of P-glycoprotein (P-gp, ABCB1), significantly different substrate and inhibitor specificities have been observed between species (Pike, 2009; Syvanen et al., 2009) . Baltes et al. (2007) demonstrated that phenytoin and levetiracetam were transported by mouse but not human Pg-p (Baltes et al., 2007) . Differences in inhibitor efficacy have also been suggested for human and mouse ABCG2 (Zhang et al., 2005) . This suggests caution when extrapolating data from mouse models to humans. The comparative specificity of substrates and inhibitors in human versus mouse ABCG2 is still unclear and warrants further investigation. In this study, the abilities of cell lines expressing human or mouse ABCG2 to efflux fluorescent substrates were compared using flow cytometry. The genomic sequence and protein expression of ABCG2 was assessed in the cell lines. A new fluorescent porphyrin substrate, purpurin-18 (Pp-18) was identified, and demonstrated to be transported by mouse and human DMD #53140 7 large cell lung cancer cell line H460 and its ABCG2-expressing subline H460 MX20 ( 20 nM mitoxantrone) (Robey et al., 2004) , the human breast cancer cell line MCF-7, its ABCG2-expressing subline MCF-7 FLV500 (500 nM flavopiridol) (Robey et al., 2001b) and its MRP1-expressing subline MCF-7 VP-16 (16 nM etoposide) (Schneider et al., 1994) ; the human adenocarcinoma cell line KB-3-1 and its P-gp-expressing subline KB-8-5-11 (250 nM colchicine) (Shen et al., 1986) . All cells were grown at 37°C in 5% CO 2 and were maintained either in RPMI or DMEM medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin. Medium was removed and cells were grown in the same medium in the absence of drug selection 5 to 30 days before assay.
The mouse fibroblast 3T3 MX15 subline was selected by exposing NIH 3T3 cells to increasing concentrations of mitoxantrone (1nM -15 nM). The Ltk-mouse cell line was developed from a subline of the BrdU-resistant strain of the L-M mouse line (Kit et al., 1963) . The Ltk-drugselected subline (Ltk-HoeR415) has been shown to have increased Abcg2 expression and function (Smith et al., 1988; Smith et al., 2009 ). The Ltk-and Ltk-HoeR415 were provided by Paul J. Smith (Cardiff University). The MEF3.8 cell line was derived from Mdr1a/b -/-Mrp1 -/-mice and the MEF3.8 M32 subline were provided by Alfred H. Schinkel (Netherlands Cancer Institute). The human ABCG2-expressing sublines used (H460 MX20 and MCF7 FLV500) have been previously characterized (Robey et al., 2001b; Robey et al., 2004 (Nguyen et al., 2011) . Samples were analyzed as previously described unless stated otherwise (Kohn et al., 2012) . In brief, samples containing the same amount of protein, 57 ng (mouse) or 20 ng (human) for ABCG2 analysis and 20 ng (human and mouse) for P-gp analysis, were used.
The target proteins were immunoprobed for ABCG2 using monoclonal BXP-53 antibody (Abcam) and for P-gp expression using monoclonal C219 antibody (Fujirebio Diagnostics, Inc.) and for tubulin using anti-α-tubulin (Cell Signaling Technologies). For quantitative data analysis, the ABCG2 and P-gp signals were normalized against α -tubulin as a loading control.
Cytotoxicity Assay. Cytotoxicity was measured with a luminescent cell viability assay (CellTiter Glo by Promega). Stock solutions of cytotoxic drugs were prepared in RPMI medium.
Cultured cells were seeded 3,000 cells/well and incubated in serial dilutions of the compound for 72 h. before assaying cell growth, as described by (Brimacombe et al., 2009 Fig. 2 ), which increased in the presence of Ko143.
Human and Mouse ABCG2 Demonstrated an Overlap in Efflux of Fluorescent
Substrates. In this study, we examined independent drug-selected mouse and human ABCG2- To evaluate fluorescent substrates of human and mouse ABCG2, we conducted efflux studies using flow cytometry. Cells were incubated with fluorescent substrates identified from the literature (Table 1) with or without inhibitor (10 µM Ko143), washed, and then allowed to efflux in substrate-free media under the same conditions. The compounds studied were mitoxantrone, Hoechst 33342, BODIPY-prazosin, rhodamine 123, daunorubicin, pheophorbide a, pyropheophorbide a methyl ester (MPPa) and chlorin e6 (Polgar et al., 2008) . Daunorubicin and rhodamine 123 were assessed because they are transported by the R482 mutant but not wildtype ABCG2 (Robey et al., 2003) . Cell fluorescence was normalized to the value derived in ABCG2-expressing cells in the presence of Ko143 (i.e., cells with fully inhibited ABCG2) and the percentage (%) difference with and without the inhibitor is displayed for ABCG2-expressing cells in Table 1 with and without a specific P-gp inhibitor (1 µM DCPQ) since they are weak substrates of P-gp.
Mitoxantrone and daunorubicin accumulation did not significantly increase in the presence of a specific P-gp inhibitor. However, BODIPY-prazosin and Hoechst 33342 accumulation did increase in the presence of a specific P-gp inhibitor (Supplemental Fig. 7 ), but the difference was smaller than that due to Abcg2 efflux (Supplemental Fig. 2 ). Therefore, our data suggest that the low baseline P-gp in the mouse cell lines is not a major participant in the transport of mitoxantrone, Hoechst 33342 and BODIPY-prazosin. Fig. 3B ). In the parental cells, a small but detectable amount of inhibitable Pp-18 efflux was observed when these cells were incubated in Pp-18 without (grey line) or with (black line) Ko143. To evaluate the ABCG2 specificity of Pp-18 among ABC transporters, we conducted efflux studies on sublines overexpressing human P-gp (KB-8-5-11) and MRP1 (VP16), and mouse P-gp (C3M) compared with their parental lines (KB-3-1, MCF7 and 3T3, respectively). Cells were incubated with Pp-18 with or without their respective transport inhibitor (20 µM verapamil for P-gp; 100 µM indomethacin for MRP1). No significant differences were observed in the accumulation of Pp-18 between parental and transporterexpressing lines for human P-gp or MRP1 (Fig. 3C ), and mouse P-gp (Fig. 3D) , though a small non-specific effect was evident in all cells. Pp-18 is a therefore a specific substrate for human and mouse ABCG2, and can be used to test the effect of inhibitors on ABCG2 efflux.
Inhibitors Demonstrated a Similar Effect on Human and Mouse ABCG2-Mediated
Efflux of Pp-18. We next examined the inhibition of Pp-18 efflux to assess reported inhibitors of ABCG2-mediated drug resistance (Table 2, Figure 2B and Supplemental was not observed ( Figure 2B ). Sulfazalazine did not inhibit either human or mouse ABCG2
efflux of Pp-18. Quercetin, sulfasalazine, NSC73306, chrysin, 17-β-estradiol, novobiocin, and vismodegib were examined at lower concentrations (10 µM), and exhibited the same relative inhibition profile against all four cell lines (Supplemental Fig. 9 ).
Given conflicting reports that cyclosporin A inhibits ABCG2 function (Ejendal and Hrycyna, 2005; Gupta et al., 2006) , we tested its ability to inhibit the efflux of Pp-18 in a dose dependent manner (Fig. 4) . We observed a dose-dependent increase in accumulation of Pp-18 when cyclosporin A (1, 5, 10, 25, 50 µM) was added. Incubation with cyclosporin A at 50 µM demonstrated a similar inhibition profile to Ko143 in the Ltk-HoeR415 subline.
This article has not been copyedited and formatted. The final version may differ from this version. Given that Pp-18 is extruded by mouse and human ABCG2 and it is not a substrate for human Pgp or MRP1 or mouse P-gp (Fig. 3) it may be useful for pre-clinical mouse models to study Table 2 (fold increase of purpurin-18 accumulation by select inhibitors) were averaged for human and mouse ABCG2. No significant differences were observed. Table 1 . This article has not been copyedited and formatted. The final version may differ from this version. 
